These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 19756533)

  • 1. Nanomaterial characterization: considerations and needs for hazard assessment and safety evaluation.
    Boverhof DR; David RM
    Anal Bioanal Chem; 2010 Feb; 396(3):953-61. PubMed ID: 19756533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of nanomaterial dispersion in solution prior to in vitro exposure using dynamic light scattering technique.
    Murdock RC; Braydich-Stolle L; Schrand AM; Schlager JJ; Hussain SM
    Toxicol Sci; 2008 Feb; 101(2):239-53. PubMed ID: 17872897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of information in nanomaterial safety data sheets and development of international standard for guidance on preparation of nanomaterial safety data sheets.
    Lee JH; Kuk WK; Kwon M; Lee JH; Lee KS; Yu IJ
    Nanotoxicology; 2013 May; 7(3):338-45. PubMed ID: 22263625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The hierarchy of environmental health and safety practices in the U.S. nanotechnology workplace.
    Engeman CD; Baumgartner L; Carr BM; Fish AM; Meyerhofer JD; Satterfield TA; Holden PA; Harthorn BH
    J Occup Environ Hyg; 2013; 10(9):487-95. PubMed ID: 23927041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanotoxicology and nanotechnology: new findings from the NIEHS and Superfund Research Program scientific community.
    Carlin DJ
    Rev Environ Health; 2014; 29(1-2):105-7. PubMed ID: 24695034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Research strategies for safety evaluation of nanomaterials. Part VI. Characterization of nanoscale particles for toxicological evaluation.
    Powers KW; Brown SC; Krishna VB; Wasdo SC; Moudgil BM; Roberts SM
    Toxicol Sci; 2006 Apr; 90(2):296-303. PubMed ID: 16407094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Research strategies for safety evaluation of nanomaterials, part V: role of dissolution in biological fate and effects of nanoscale particles.
    Borm P; Klaessig FC; Landry TD; Moudgil B; Pauluhn J; Thomas K; Trottier R; Wood S
    Toxicol Sci; 2006 Mar; 90(1):23-32. PubMed ID: 16396841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of nanomaterials for toxicological studies.
    Powers KW; Carpinone PL; Siebein KN
    Methods Mol Biol; 2012; 926():13-32. PubMed ID: 22975954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exposure assessment approaches for engineered nanomaterials.
    Abbott LC; Maynard AD
    Risk Anal; 2010 Nov; 30(11):1634-44. PubMed ID: 20626687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Research strategy for evaluation methods of the manufactured nanomaterials in NIHS and importance of the chronic health effects studies].
    Hirose A; Nishimura T; Kanno J
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2009; (127):15-25. PubMed ID: 20306702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Manufactured nanomaterials: categorization and approaches to hazard assessment.
    Gebel T; Foth H; Damm G; Freyberger A; Kramer PJ; Lilienblum W; Röhl C; Schupp T; Weiss C; Wollin KM; Hengstler JG
    Arch Toxicol; 2014 Dec; 88(12):2191-211. PubMed ID: 25326817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Research strategies for safety evaluation of nanomaterials, part IV: risk assessment of nanoparticles.
    Tsuji JS; Maynard AD; Howard PC; James JT; Lam CW; Warheit DB; Santamaria AB
    Toxicol Sci; 2006 Jan; 89(1):42-50. PubMed ID: 16177233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale of genotoxicity testing of nanomaterials: regulatory requirements and appropriateness of available OECD test guidelines.
    Warheit DB; Donner EM
    Nanotoxicology; 2010 Dec; 4():409-13. PubMed ID: 20925448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotoxicity investigations on nanomaterials.
    Oesch F; Landsiedel R
    Arch Toxicol; 2012 Jul; 86(7):985-94. PubMed ID: 22456836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research strategies for safety evaluation of nanomaterials, part II: toxicological and safety evaluation of nanomaterials, current challenges and data needs.
    Holsapple MP; Farland WH; Landry TD; Monteiro-Riviere NA; Carter JM; Walker NJ; Thomas KV
    Toxicol Sci; 2005 Nov; 88(1):12-7. PubMed ID: 16120754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanomaterial health effects--part 1: background and current knowledge.
    Powell MC; Kanarek MS
    WMJ; 2006 Mar; 105(2):16-20. PubMed ID: 16628969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The carcinogenic potential of nanomaterials, their release from products and options for regulating them.
    Becker H; Herzberg F; Schulte A; Kolossa-Gehring M
    Int J Hyg Environ Health; 2011 Jun; 214(3):231-8. PubMed ID: 21168363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicological aspects for nanomaterial in humans.
    Dusinska M; Magdolenova Z; Fjellsbø LM
    Methods Mol Biol; 2013; 948():1-12. PubMed ID: 23070759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic evaluation of nanomaterial toxicity: utility of standardized materials and rapid assays.
    Harper SL; Carriere JL; Miller JM; Hutchison JE; Maddux BL; Tanguay RL
    ACS Nano; 2011 Jun; 5(6):4688-97. PubMed ID: 21609003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advancing risk assessment of engineered nanomaterials: application of computational approaches.
    Gajewicz A; Rasulev B; Dinadayalane TC; Urbaszek P; Puzyn T; Leszczynska D; Leszczynski J
    Adv Drug Deliv Rev; 2012 Dec; 64(15):1663-93. PubMed ID: 22664229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.